Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies

Author:

Piha‐Paul Sarina A.1ORCID,Oh Do‐Youn2,Ueno Makoto3,Malka David4,Chung Hyun Cheol5,Nagrial Adnan6,Kelley Robin K.7,Ros Willeke8,Italiano Antoine9ORCID,Nakagawa Kazuhiko10,Rugo Hope S.11,Braud Filippo12,Varga Andrea Iolanda13,Hansen Aaron14,Wang Hui15,Krishnan Suba16,Norwood Kevin G.16,Doi Toshihiko17

Affiliation:

1. Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Internal Medicine Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine Seoul Republic of Korea

3. Department of Gastroenterology Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center Yokohama Japan

4. Département de Médecine Oncologique Gustave Roussy, Université Paris‐Saclay Villejuif France

5. Department of Medical Oncology, Yonsei Cancer Center Yonsei University College of Medicine Seoul Republic of Korea

6. Blacktown Cancer and Haematology Centre Blacktown Hospital and University of Sydney Sydney New South Wales Australia

7. Division of Hematology/Oncology University of California San Francisco San Francisco California USA

8. Division of Pharmacology Antoni van Leeuwenhoek Ziekenhuis Amsterdam Netherlands

9. Early phase Trials and Sarcoma Units Institut Bergonié Bordeaux France

10. Department of Medical Oncology Kindai University Hospital Osaka Japan

11. Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California USA

12. Department of Oncology and Hemato‐Oncology University of Milan and Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Tumori Milan Italy

13. Department of Drug Development Gustave Roussy, Université Paris‐Saclay Villejuif France

14. Division of Medical Oncology Princess Margaret Cancer Centre Toronto Ontario Canada

15. Biostatistical and Research Decision Sciences, Merck & Co., Inc. Kenilworth New Jersey USA

16. Oncology Late Development, Merck & Co., Inc. Kenilworth New Jersey USA

17. Department of Experimental Therapeutics/Gastrointestinal Oncology National Cancer Center Hospital East Kashiwa Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

Cited by 348 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3